- $400.42m
- $411.16m
- 16
- 68
- 89
- 59
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st May | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | 0.27 | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
CytoDyn Inc. is a clinical-stage biotechnology company. The Company is focused on the development and commercialization of leronlimab, an investigational humanized IgG4 monoclonal antibody (mAb) that is designed to bind to C-C chemokine receptor type 5 (CCR5), a protein on the surface of certain immune system cells. It has studied leronlimab in multiple therapeutic areas, including infectious disease, oncology, and autoimmune conditions. The Company has conducted clinical trials of leronlimab as a viral entry inhibitor for human immunodeficiency virus (HIV), believed to competitively bind to the N-terminus and second extracellular loop of the CCR5 receptor. For immunology, the CCR5 receptor is believed to be implicated in immune-mediated illnesses such as Metabolic dysfunction-associated steatohepatitis. It has a joint development agreement with a third-party generative artificial intelligence (AI) drug discovery and development company to develop one or more longer-acting molecules.
Directors
- Tanya Urbach CHM
- Antonio Migliarese PRE (38)
- Christopher Recknor COO (56)
- Michael Mulholland SVF (68)
- Nitya Ray CTO (68)
- Mahboob Rahman CSO
- Arian Colachis VPR (58)
- Scott Kelly OTH (51)
- Seenu Srinivasan OTH
- Gordon Gardiner DRC (52)
- Jordan Naydenov IND (60)
- Last Annual
- May 31st, 2024
- Last Interim
- February 28th, 2025
- Incorporated
- August 27th, 2018
- Public Since
- November 17th, 2005
- No. of Shareholders
- 1,000
- No. of Employees
- 9
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
Pink Sheets on Nasdaq- Shares in Issue
- 1,232,433,000
- Address
- 1111 Main St Ste 660, VANCOUVER, 98660-2970
- Web
- https://www.cytodyn.com/
- Phone
- +1 3609808524
- Auditors
- Marcum LLP
Upcoming Events for CYDY
Q1 2026 Cytodyn Inc Earnings Release
Similar to CYDY
Actavia Life Sciences
Pink Sheets on Nasdaq
Acura Pharmaceuticals
Pink Sheets on Nasdaq
Adhera Therapeutics
Pink Sheets on Nasdaq
Ramoil Management
Pink Sheets on Nasdaq
Adynxx
Pink Sheets on Nasdaq
FAQ
What is the Cytodyn share price?
As of Today at 20:09 UTC, shares in Cytodyn are trading at $0.32. This share price information is delayed by 15 minutes.
How has the Cytodyn share price performed this year?
Shares in Cytodyn last closed at $0.32 and the price had moved by +133.74% over the past 365 days. In terms of relative price strength the Cytodyn share price has outperformed the S&P500 Index by +116.74% over the past year.
What are the analyst and broker recommendations for Cytodyn?
The overall consensus recommendation for Cytodyn is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Cytodyn dividend yield?
Cytodyn does not currently pay a dividend.
Does Cytodyn pay a dividend?
Cytodyn does not currently pay a dividend.
When does Cytodyn next pay dividends?
Cytodyn does not currently pay a dividend.
How do I buy Cytodyn shares?
To buy shares in Cytodyn you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Cytodyn?
As of the previous close price of $0.32, shares in Cytodyn had a market capitalisation of $400.42m.
Where are Cytodyn shares listed?
Here are the trading details for Cytodyn:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: CYDY
What kind of share is Cytodyn?
Based on an overall assessment of its quality, value and momentum Cytodyn is currently classified as a Turnaround. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Cytodyn share price forecast for 2025?
The analyst consensus target price for shares in Cytodyn is $4.00. That is 1131.15% above the last closing price of $0.32.
Analysts covering Cytodyn currently have a consensus Earnings Per Share (EPS) forecast of for the next financial year.
Find out moreWhat is the trend in the Cytodyn share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Cytodyn. Over the past six months, its share price has outperformed the S&P500 Index by +156.51%.
As of the last closing price of $0.32, shares in Cytodyn were trading +88.34% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Cytodyn PE Ratio?
The Cytodyn PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.32.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Cytodyn?
Cytodyn's management team is headed by:
- Tanya Urbach - CHM
- Antonio Migliarese - PRE
- Christopher Recknor - COO
- Michael Mulholland - SVF
- Nitya Ray - CTO
- Mahboob Rahman - CSO
- Arian Colachis - VPR
- Scott Kelly - OTH
- Seenu Srinivasan - OTH
- Gordon Gardiner - DRC
- Jordan Naydenov - IND